mb07133
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2003 (NCT00073736)
Timeline
Indications
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-amino-1-(5-o-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1h)-pyrimidinone
- 4-amino-1-(5-o-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)-beta-d-arabinofuranosyl)-2(1h)-pyrimidinone
- mb07133
- mb07133
- mb07133
- mb 07133
- mb-07133
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06141109 | Phase 1/Phase 2 (Phase 2) | Jan 18, 2022 | Jinlin University, Xintong Pharmacy Company |
| NCT06141096 | Phase 2 | Jan 17, 2020 | Jinlin University, Xintong Pharmacy Company |
| NCT00073736 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2003 | Ligand Pharmaceuticals, Metabasis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jinlin University | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Xintong Pharmacy Company | Government | 2 | 2 | 1 | 2020 |
| Ligand Pharmaceuticals | For profit | 1 | 1 | 1 | 2003 |
| Metabasis | For profit | 1 | 0 | 1 | 2003 |
4 organizations
Page 1 / 1